Skip to main content
Premium Trial:

Request an Annual Quote Raises $5M in Private Funding

NEW YORK — said on Tuesday that it has raised $5 million in venture capital financing.

The financing was led by Lerer Hippeau and included Red Sea Ventures, Global Founders Capital, XRC Labs, Correlation Ventures, Red Antler, Mucker Capital, and Gaingels. was founded in 2016 as a direct-to-consumer marketplace for genomic data analysis and management tools, as well as a provider of DNA data storage. With the new funding, the Los Angeles-based company said it will expand its offerings, including adding a 30X whole-genome sequencing service.

"Within the next five years, we expect that between 100 million and 2 billion human genomes will be sequenced," Founder and CEO Brandon Colby said in a statement. "This capital raise allows us to rapidly expand our unique solutions that unlock the true value of genetic data and directly empower the individual."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.